Axatilimab

Axatilimab 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Myelofibrosis (MF)、Chronic Myelomonocytic Leukemia (CMML)。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Axatilimab 研究

• Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors

  I 期 / II 期招募中美国NCT06320405

• Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

  I 期招募中美国NCT06488378

• A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

  III 期招募中美国澳大利亚奥地利加拿大NCT06585774

• A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)

  II 期招募中美国比利时德国意大利NCT07124078

• Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation

  II 期招募中美国NCT05491226

• Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia

  I 期 / II 期招募中美国NCT06523556

• Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease

  II 期招募中美国NCT06663722

• Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)

  I 期 / II 期招募中美国NCT07128381

• Axatilimab for Sclerotic Chronic Graft-versus-Host Disease

  II 期招募中美国NCT07011810

• A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

  II 期招募中美国澳大利亚比利时加拿大NCT04710576

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。